T Cell-Nanoparticle Conjugates for Latent Virus Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for viral infections, such as HIV, face challenges in targeting and eliminating latent reservoirs of infected cells, as resting memory CD4+ T cells remain dormant and are not effectively targeted by the immune system or antiviral therapies.
Innovation Solution
The use of agent-loaded nanoparticles conjugated to virus-specific CD8+ T lymphocytes to deliver latency-reversing drugs and antiviral agents directly to virally infected tissues, allowing for localized and controlled activation of latent virus expression and elimination of infected cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral therapies are used, then actively infected cells are suppressed, but latently infected resting memory CD4+ T cells are not effectively targeted and remain dormant
Solution Approach 1:
The patent applies preliminary action by using latency-reversing drugs (LRDs) to activate latent virus expression in resting memory CD4+ T cells before the immune system can target them. This transforms the dormant infected cells into actively expressing virus, making them susceptible to immune recognition and elimination. The LRDs are delivered via nanoparticles that are conjugated to T cells, ensuring the activation occurs at the right time and place.
Solution Approach 2:
The patent achieves universality by creating a dual-function system where nanoparticles serve both as delivery vehicles for latency-reversing drugs and as carriers for antiviral agents. The same nanoparticle structure can deliver different therapeutic agents depending on the infection state, making the treatment approach versatile against both latent and active viral infections.
2Ease of operation
If the immune system targets infected cells, then actively expressing virus is eliminated, but resting memory CD4+ T cells in latent state are not effectively targeted
Solution Approach 1:
The patent uses preliminary action by pre-activating latent virus expression with LRDs before immune system engagement. This ensures that when the immune system targets the cells, the virus is already expressing and the cells are visible to immune surveillance, thereby improving the reliability of latent reservoir elimination while maintaining ease of immune system operation.
Solution Approach 2:
The patent introduces LRDs as intermediaries that mediate between the latent infected cells and the immune system. These drugs act as a bridge by inducing viral expression, which then enables the immune system to recognize and eliminate the previously hidden latent reservoirs, effectively connecting the two previously disconnected targets.
3Reliability
If latency-reversing drugs are administered systemically, then latent virus is activated, but the activation is not localized and may cause widespread immune activation
Solution Approach 1:
The patent applies local quality by delivering LRDs through nanoparticles that are conjugated to virus-specific T cells. This ensures that the drug activation occurs locally at the site of viral infection rather than systemically throughout the body. The T cell-nanoparticle conjugates accumulate at infected tissues, providing localized virus activation and minimizing widespread immune activation and associated harmful effects.
Solution Approach 2:
The patent implements self-service by using the virus-specific T cells themselves as the delivery vehicle for the latency-reversing drugs. The T cells naturally home to infected tissues, and by conjugating nanoparticles carrying LRDs to these T cells, the system uses the T cells' inherent targeting capability to deliver the drugs precisely where needed, eliminating the need for external targeting mechanisms.
4Measurement precision
If nanoparticles are conjugated to T cells for localized delivery, then drug delivery precision is improved, but the system complexity increases
Solution Approach 1:
The patent applies merging by combining the nanoparticle delivery system with the T cell targeting system into a single integrated conjugate. This unified structure leverages the precision targeting of T cells while maintaining the drug delivery capabilities of nanoparticles, achieving high delivery precision without requiring separate complex systems for targeting and delivery.
Solution Approach 2:
The patent achieves universality by creating a multi-functional nanoparticle-T cell conjugate that simultaneously performs immune surveillance, drug delivery, and localized virus activation. This single system replaces what would otherwise require multiple separate components, thereby improving delivery precision while managing overall system complexity through functional integration.
Data Source
AI summary
The invention provides compositions and methods for delivering an agent to virally infected tissues and/or cells of a subject by conjugating agent-loaded nanoparticles to virus-specific T cells, such as cytotoxic T lymphocytes. The agent may be a latency-reversing drug (LRD), an antiviral agent and/or an agent that enhances cytotoxic efficacy of T lymphocytes.